5 Minutes to Stay Current

Urinary peptidome and diabetic retinopathy in the DIRECT-protect 1 and 2 trials

Diabetic MedicineCurovic VR, Magalhães P, He T, et al. | July 27, 2021

Advertisement

This study attempted to explore the urinary peptidome to presence and deterioration of diabetic retinopathy (DR) in a post hoc analysis of trials investigating the effect of candesartan on progression of DR in type 1 and type 2 diabetes, respectively. Researchers conducted baseline urinary peptidomic analysis on a random selection of 783 and 792 subjects in two randomized controlled trials, DIRECT-Protect 1 and 2, respectively. They compared peptide levels to baseline EDTRS levels in a discovery set of 2/3 of the participants from DIRECT-Protect 1. Several urinary peptides (mainly collagen) associated with the presence of DR were distinguished, nevertheless, they could not be conclusively correlated with worsening of DR.

Advertisement